SecBot SecBot

AVIR

Atea Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. MA· CIK 0001593899 Biotech & Drug Discovery
$4.16 +0.01 (+0.12%)
Oct 27 4:00 PM ET · prev $4.16
Market cap
$324.0M
Small cap
Consensus
Buy
78% Buy or better · 9 analysts
Median target
$8.50
+104% · range $7.00–10.00
Next earnings
Nov 5
in 9 days · EPS est. −$0.51
1 year
+28.2%
from $3.25 · Oct 27
30 days
−19.9%
from $5.20
52-week range
$2.96–6.15
−32% from high · low Nov 14
Avg volume 20D
295.1K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$25.4K
1 buyer · 0 sellers · since Jan 31
New fund stakes
0
Q2 2026 13F · 0 exits
Reddit crowd
50°
Neutral · 1 mention this week
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 5, 2026
Strongest NEUTRAL Tang Capital Management, led by Kevin Tang, filed a Schedule 13G converting its prior Schedule 13D status…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $25.4K at an average $4.17. No open-market sales.

  • InstitutionsBULLISH

    Q2 2026: 13 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    7 of 9 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.545 → −$0.505 over 90 days. 1 up, 1 down in 30 days.

  • TrendDOWNTREND

    19% below its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
NORTHERN TRUST CORPADD755,239$3.5M
BARCLAYS PLCDOUBLED348,653$1.6M
Quantinno Capital Management LPDOUBLED242,302$1.1M
WELLINGTON MANAGEMENT GROUP LLPDOUBLED206,785$961.6K
CITADEL ADVISORS LLCDOUBLED157,224$731.1K
BNP PARIBAS FINANCIAL MARKETSTRIM78,721$366.1K
WELLS FARGO & COMPANY/MNDOUBLED59,716$277.7K
Russell Investments Group, Ltd.ADD54,892$254.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 78% rate it Buy or better
Strong Buy3Buy4Hold2Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +104%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Aug 13, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Reddit
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 1 1 in posts · 0 in comments
Recent posts
r/pennystocks Neutral 5d ago
22 OCT 2026 , WHAT ARE THE BIGGEST LOSERS AND WHY ?
1 upvotes · 6 comments
All social signals and their track records

Insider ledger

Form 4
$25.4K
bought · 1 insider
$0
sold · 0 insiders
−0.2%
vs their $4.17 cost
DateInsiderTypeValue
Jun 18, 2026
Murphy Polly A.
Director
AWARD26,700 sh
Jun 18, 2026
Lucidi Bruno
Director
AWARD26,700 sh
Jun 18, 2026
Polsky Bruce
Director
AWARD26,700 sh
Jun 18, 2026
DUNCAN BARBARA GAYLE
Director
EXERCISE29,600 sh
Jun 18, 2026
Polsky Bruce
Director
EXERCISE29,600 sh
Jun 18, 2026
Polsky Bruce
Director
AWARD37,700 sh
Jun 18, 2026
Murphy Polly A.
Director
EXERCISE29,600 sh
Jun 18, 2026
Adams Jerome M.
Director
EXERCISE29,600 sh

Earnings setup

Estimates
Nov 5
reports in 9 days
−$0.51
EPS estimate, this quarter
+7%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.51-$0.59–-$0.42+7.3%$0.00
Next Q-$0.57-$0.72–-$0.42-15.2%$0.00
Current FY-$1.99-$2.21–-$1.76-3.1%$0.00
Next FY-$1.48-$1.76–-$1.20-6.9%$30.0M

Washington

Corporate Lobbying

6 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Jul 28, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Short interest report
🔒 Fresh data, subscribers only
Oct 6, 2026 SEC
Tang Capital Management, led by Kevin Tang, filed a Schedule 13G converting its prior Schedule 13D status for Atea…
SC 13G — Impact 4/10
Jul 14, 2026 Press
Atea Pharmaceuticals initiated a first-in-human Phase 1 trial of AT-587 for hepatitis E virus (HEV), a disease with no…
Impact 5/10
Jun 30, 2026 Inst.
NORTHERN TRUST CORP — ADD
755,239 shares ($3.5M)
Jun 30, 2026 Inst.
BARCLAYS PLC — DOUBLED
348,653 shares ($1.6M)
Jun 18, 2026 Insider
Murphy Polly A. was granted 26,700 shares
Director
Jun 18, 2026 Insider
Lucidi Bruno was granted 26,700 shares
Director
Jun 18, 2026 Insider
Polsky Bruce was granted 26,700 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
AVIR Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Oct 15, 2026
Short interest
🔒 Fresh data, subscribers only
Sep 9, 2026
Trial readout
T-90d Trial Readout: Bemnifosbuvir-Ruzasvir (Phase 3)
Trial: C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Sponsor: Atea Pharmaceuticals, Inc. Phase: Phase 3 |…
Sep 6, 2026
Trial readout
T-90d Trial Readout: Bemnifosbuvir-Ruzasvir (Phase 3)
Trial: C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Sponsor: Atea Pharmaceuticals, Inc. Phase: Phase 3 |…
Sep 2, 2026
Trial readout
T-90d Trial Readout: Bemnifosbuvir-Ruzasvir (Phase 3)
Trial: C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Sponsor: Atea Pharmaceuticals, Inc. Phase: Phase 3 |…
Aug 12, 2026
Earnings
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential…

SecBot reports

4 filings · 2 press releases · 0 bullish · 1 bearish · 3 neutral
All AVIR filing & press-release reports (6)